Atopic dermatitis in 32 children treated with dupilumab in real life. A new contribution.
作者信息
Betlloch-Mas Isabel, Armengol-García María, Jara-Rico Noelia, Hernández-Quiles Ruben, DeGracia Laura Berbegal
机构信息
Department of Clinical Medicine Miguel Hernández University Alicante Spain.
Department of Dermatology Dr. Balmis de Alicante General University Hospital Alicante Spain.
出版信息
Skin Health Dis. 2024 Jul 3;4(5):e413. doi: 10.1002/ski2.413. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
Atopic dermatitis in 32 children treated with dupilumab in real life. A new contribution.32例儿童特应性皮炎患者在实际临床中接受度普利尤单抗治疗：一项新的研究贡献
Skin Health Dis. 2024 Jul 3;4(5):e413. doi: 10.1002/ski2.413. eCollection 2024 Oct.
2
Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience.度普利尤单抗治疗中度和重度特应性皮炎：真实世界经验
Postepy Dermatol Alergol. 2023 Dec;40(6):747-752. doi: 10.5114/ada.2023.133818. Epub 2024 Jan 8.
3
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.度普利尤单抗为中度至重度特应性皮炎成人患者提供快速且持续的具有临床意义的缓解。
Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307.
4
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.一项为期 16 周的随机 III 期研究：度普利尤单抗对 6 个月至 5 岁中重度特应性皮炎儿童的实验室安全性。
Paediatr Drugs. 2023 Jan;25(1):67-77. doi: 10.1007/s40272-022-00553-8. Epub 2022 Dec 19.
5
Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.成人特应性皮炎患者接受度普利尤单抗治疗的评估：一项单中心真实世界经验。
J Cosmet Dermatol. 2022 Oct;21(10):4781-4787. doi: 10.1111/jocd.14785. Epub 2022 Jan 30.
6
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.度普利尤单抗治疗特应性皮炎患者的长期疗效：RELIEVE-AD研究3年随访结果
Dermatol Ther (Heidelb). 2023 Sep;13(9):2107-2120. doi: 10.1007/s13555-023-00965-5. Epub 2023 Aug 8.
7
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的临床意义：一项随机临床试验的事后分析。
Am J Clin Dermatol. 2020 Feb;21(1):119-131. doi: 10.1007/s40257-019-00478-y.
8
Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.儿童中重度特应性皮炎患者接受度普利尤单抗治疗后出现银屑病样皮炎。
Pediatr Dermatol. 2021 Nov;38(6):1500-1505. doi: 10.1111/pde.14820. Epub 2021 Oct 14.
9
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.度普利尤单抗治疗可使成人特应性皮炎患者的症状和生活质量在两年内持续改善。
Dermatol Ther (Heidelb). 2021 Dec;11(6):2147-2157. doi: 10.1007/s13555-021-00630-9. Epub 2021 Oct 29.
10
Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020.特应性皮炎患儿接受度普利尤单抗治疗后的疫苗接种推荐意见：共识会议，2020 年。
Am J Clin Dermatol. 2021 Jul;22(4):443-455. doi: 10.1007/s40257-021-00607-6. Epub 2021 Jun 2.
本文引用的文献
1
Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.真实世界中接受度普利单抗治疗中重度特应性皮炎儿童的结局：一项英国单中心回顾性观察研究。
Clin Exp Dermatol. 2024 May 21;49(6):578-583. doi: 10.1093/ced/llae013.
2
Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study.6 岁以下中重度特应性皮炎儿童使用度普利尤单抗的有效性和安全性：一项回顾性真实世界研究。
Dermatology. 2024;240(2):337-342. doi: 10.1159/000535282. Epub 2023 Nov 30.
3
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.儿童特应性皮炎患者 6-11 岁接受度普利尤单抗治疗：一项多中心真实世界研究。
Paediatr Drugs. 2022 Nov;24(6):671-678. doi: 10.1007/s40272-022-00531-0. Epub 2022 Aug 27.
4
Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study.度普利尤单抗治疗中重度特应性皮炎儿科患者的疗效和安全性：一项真实世界研究。
Arch Dermatol Res. 2023 Apr;315(3):467-472. doi: 10.1007/s00403-022-02380-w. Epub 2022 Aug 21.
5
Treatment of children from 6 to 11 years old affected by moderate-severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy.度普利尤单抗治疗6至11岁中重度特应性皮炎患儿：来自意大利单中心真实世界经验的首个观点
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e478-e480. doi: 10.1111/jdv.17963. Epub 2022 Feb 3.
Zotero 插件